The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

At its second attempt, Novartis has won FDA approval for its cholesterol lowering drug inclisiran, which can reduce levels with just two injections a year. The FDA has approved the drug under the ...

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Although elevated oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) levels predicted major adverse cardiovascular events (MACE) in patients with a recent acute coronary syndrome (ACS) ...

A new clinical guideline released by the ACC and the American Heart Association (AHA) includes new evidence and updated recommendations for managing patients with an ...